Societal costs of exposure to toxic substances: economic and health costs of four case studies that are candidates for environmental causation.
Identifieur interne : 001547 ( PubMed/Corpus ); précédent : 001546; suivant : 001548Societal costs of exposure to toxic substances: economic and health costs of four case studies that are candidates for environmental causation.
Auteurs : T. Muir ; M. ZegaracSource :
- Environmental health perspectives [ 0091-6765 ] ; 2001.
English descriptors
- KwdEn :
- Canada, Child, Cost of Illness, Developmental Disabilities (economics), Developmental Disabilities (etiology), Environmental Health (economics), Environmental Pollutants (adverse effects), Environmental Pollutants (economics), Epidemiologic Studies, Health Care Costs (statistics & numerical data), Humans, Hypothyroidism (economics), Hypothyroidism (etiology), Parkinson Disease (economics), Parkinson Disease (etiology), Public Health (economics), Social Conditions, United States.
- MESH :
- chemical , adverse effects : Environmental Pollutants.
- chemical , economics : Environmental Pollutants.
- geographic : Canada, United States.
- economics : Developmental Disabilities, Environmental Health, Hypothyroidism, Parkinson Disease, Public Health.
- etiology : Developmental Disabilities, Hypothyroidism, Parkinson Disease.
- statistics & numerical data : Health Care Costs.
- Child, Cost of Illness, Epidemiologic Studies, Humans, Social Conditions.
Abstract
Four outcomes that evidence suggests are candidates for "environmental causation" were chosen for analysis: diabetes, Parkinson's disease (PD), neurodevelopmental effects and hypothyroidism, and deficits in intelligence quotient (IQ). These are an enormous burden in the United States, Canada, and other industrial countries. We review findings on actual social and economic costs, construct estimates of some of the costs from pertinent sources, and provide several hypothetical examples consistent with published evidence. Many detailed costs are estimated, but these are fragmented and missing in coverage and jurisdiction. Nonetheless, the cumulative costs identified are very large, totaling $568 billion to $793 billion per year for Canada and the United States combined. Partial Canadian costs alone are $46 billion to $52 billion per year. Specifics include diabetes (United States and Canada), $128 billion per year; PD in the United States, $13 billion to $28.5 billion per year; neurodevelopmental deficits and hypothryoidism are endemic and, including estimates of costs of childhood disorders that evidence suggests are linked, amount to $81.5 billion to $167 billion per year for the United States and $2 billion per year in Ontario; loss of 5 IQ points cost $30 billion per year in Canada and $275 billion to $326 billion per year in the United States; and hypothetical dynamic economic impacts cost another $19 billion to $92 billion per year for the United States and Canada combined. Reasoned arguments based on the weight of evidence can support the hypothesis that at least 10%, up to 50% of these costs are environmentally induced--between $57 billion and $397 billion per year.
PubMed: 11744507
Links to Exploration step
pubmed:11744507Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Societal costs of exposure to toxic substances: economic and health costs of four case studies that are candidates for environmental causation.</title><author><name sortKey="Muir, T" sort="Muir, T" uniqKey="Muir T" first="T" last="Muir">T. Muir</name><affiliation><nlm:affiliation>Great Lakes and Corporate Affairs, Environment Canada-Ontario Region, Burlington, Ontario, Canada. tom.muir@ec.gc.ca</nlm:affiliation></affiliation></author><author><name sortKey="Zegarac, M" sort="Zegarac, M" uniqKey="Zegarac M" first="M" last="Zegarac">M. Zegarac</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2001">2001</date><idno type="RBID">pubmed:11744507</idno><idno type="pmid">11744507</idno><idno type="wicri:Area/PubMed/Corpus">001547</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001547</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Societal costs of exposure to toxic substances: economic and health costs of four case studies that are candidates for environmental causation.</title><author><name sortKey="Muir, T" sort="Muir, T" uniqKey="Muir T" first="T" last="Muir">T. Muir</name><affiliation><nlm:affiliation>Great Lakes and Corporate Affairs, Environment Canada-Ontario Region, Burlington, Ontario, Canada. tom.muir@ec.gc.ca</nlm:affiliation></affiliation></author><author><name sortKey="Zegarac, M" sort="Zegarac, M" uniqKey="Zegarac M" first="M" last="Zegarac">M. Zegarac</name></author></analytic><series><title level="j">Environmental health perspectives</title><idno type="ISSN">0091-6765</idno><imprint><date when="2001" type="published">2001</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Canada</term><term>Child</term><term>Cost of Illness</term><term>Developmental Disabilities (economics)</term><term>Developmental Disabilities (etiology)</term><term>Environmental Health (economics)</term><term>Environmental Pollutants (adverse effects)</term><term>Environmental Pollutants (economics)</term><term>Epidemiologic Studies</term><term>Health Care Costs (statistics & numerical data)</term><term>Humans</term><term>Hypothyroidism (economics)</term><term>Hypothyroidism (etiology)</term><term>Parkinson Disease (economics)</term><term>Parkinson Disease (etiology)</term><term>Public Health (economics)</term><term>Social Conditions</term><term>United States</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Environmental Pollutants</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Environmental Pollutants</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term><term>United States</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Developmental Disabilities</term><term>Environmental Health</term><term>Hypothyroidism</term><term>Parkinson Disease</term><term>Public Health</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Developmental Disabilities</term><term>Hypothyroidism</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Health Care Costs</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Child</term><term>Cost of Illness</term><term>Epidemiologic Studies</term><term>Humans</term><term>Social Conditions</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Four outcomes that evidence suggests are candidates for "environmental causation" were chosen for analysis: diabetes, Parkinson's disease (PD), neurodevelopmental effects and hypothyroidism, and deficits in intelligence quotient (IQ). These are an enormous burden in the United States, Canada, and other industrial countries. We review findings on actual social and economic costs, construct estimates of some of the costs from pertinent sources, and provide several hypothetical examples consistent with published evidence. Many detailed costs are estimated, but these are fragmented and missing in coverage and jurisdiction. Nonetheless, the cumulative costs identified are very large, totaling $568 billion to $793 billion per year for Canada and the United States combined. Partial Canadian costs alone are $46 billion to $52 billion per year. Specifics include diabetes (United States and Canada), $128 billion per year; PD in the United States, $13 billion to $28.5 billion per year; neurodevelopmental deficits and hypothryoidism are endemic and, including estimates of costs of childhood disorders that evidence suggests are linked, amount to $81.5 billion to $167 billion per year for the United States and $2 billion per year in Ontario; loss of 5 IQ points cost $30 billion per year in Canada and $275 billion to $326 billion per year in the United States; and hypothetical dynamic economic impacts cost another $19 billion to $92 billion per year for the United States and Canada combined. Reasoned arguments based on the weight of evidence can support the hypothesis that at least 10%, up to 50% of these costs are environmentally induced--between $57 billion and $397 billion per year.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11744507</PMID><DateCreated><Year>2001</Year><Month>12</Month><Day>17</Day></DateCreated><DateCompleted><Year>2002</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2014</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0091-6765</ISSN><JournalIssue CitedMedium="Print"><Volume>109 Suppl 6</Volume><PubDate><Year>2001</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Environmental health perspectives</Title><ISOAbbreviation>Environ. Health Perspect.</ISOAbbreviation></Journal><ArticleTitle>Societal costs of exposure to toxic substances: economic and health costs of four case studies that are candidates for environmental causation.</ArticleTitle><Pagination><MedlinePgn>885-903</MedlinePgn></Pagination><Abstract><AbstractText>Four outcomes that evidence suggests are candidates for "environmental causation" were chosen for analysis: diabetes, Parkinson's disease (PD), neurodevelopmental effects and hypothyroidism, and deficits in intelligence quotient (IQ). These are an enormous burden in the United States, Canada, and other industrial countries. We review findings on actual social and economic costs, construct estimates of some of the costs from pertinent sources, and provide several hypothetical examples consistent with published evidence. Many detailed costs are estimated, but these are fragmented and missing in coverage and jurisdiction. Nonetheless, the cumulative costs identified are very large, totaling $568 billion to $793 billion per year for Canada and the United States combined. Partial Canadian costs alone are $46 billion to $52 billion per year. Specifics include diabetes (United States and Canada), $128 billion per year; PD in the United States, $13 billion to $28.5 billion per year; neurodevelopmental deficits and hypothryoidism are endemic and, including estimates of costs of childhood disorders that evidence suggests are linked, amount to $81.5 billion to $167 billion per year for the United States and $2 billion per year in Ontario; loss of 5 IQ points cost $30 billion per year in Canada and $275 billion to $326 billion per year in the United States; and hypothetical dynamic economic impacts cost another $19 billion to $92 billion per year for the United States and Canada combined. Reasoned arguments based on the weight of evidence can support the hypothesis that at least 10%, up to 50% of these costs are environmentally induced--between $57 billion and $397 billion per year.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muir</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Great Lakes and Corporate Affairs, Environment Canada-Ontario Region, Burlington, Ontario, Canada. tom.muir@ec.gc.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zegarac</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Environ Health Perspect</MedlineTA><NlmUniqueID>0330411</NlmUniqueID><ISSNLinking>0091-6765</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004785">Environmental Pollutants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Child Psychol Psychiatry. 1989 Mar;30(2):219-30</RefSource><PMID Version="1">2708462</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabet Med. 1989 Mar;6(2):164-70</RefSource><PMID Version="1">2522861</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pediatr. 1993 Apr;122(4):543-9</RefSource><PMID Version="1">8463898</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroepidemiology. 1993;12(4):219-28</RefSource><PMID Version="1">8272181</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 1994 Apr;78(4):809A-809F</RefSource><PMID Version="1">8157701</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Environ Res. 1994 Apr;65(1):42-55</RefSource><PMID Version="1">8162884</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Environ Res. 1994 Jul;66(1):105-24</RefSource><PMID Version="1">8013434</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Environ Res. 1995 Jul;70(1):1-6</RefSource><PMID Version="1">8603652</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1996 Sep 12;335(11):783-9</RefSource><PMID Version="1">8703183</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 1996 Dec;19(12):1416-9</RefSource><PMID Version="1">8941474</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabet Med. 1997 Aug;14(8):686-92</RefSource><PMID Version="1">9272596</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacoeconomics. 1997 Oct;12(4):486-98</RefSource><PMID Version="1">10174314</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Toxicol Ind Health. 1998 Jan-Apr;14(1-2):103-20</RefSource><PMID Version="1">9460172</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1998 May;13(3):406-13</RefSource><PMID Version="1">9613729</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Can J Public Health. 1998 May-Jun;89 Suppl 1:S31-6, S34-40</RefSource><PMID Version="1">9654790</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacoeconomics. 1998 Sep;14(3):299-312</RefSource><PMID Version="1">10186468</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1999 Aug 19;341(8):549-55</RefSource><PMID Version="1">10451459</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacoeconomics. 1999 Jul;16(1):59-69</RefSource><PMID Version="1">10539122</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pediatrics. 2000 Mar;105(3 Pt 1):515-22</RefSource><PMID Version="1">10699102</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Environ Health Perspect. 2000 Jun;108 Suppl 3:401-4</RefSource><PMID Version="1">10852835</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 2000 Nov;85(11):3975-87</RefSource><PMID Version="1">11095417</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Chronic Dis. 1973 Apr;26(4):243-54</RefSource><PMID Version="1">4714571</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Med Scand Suppl. 1983;671:19-27</RefSource><PMID Version="1">6576620</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Endocrinol (Oxf). 1984 Sep;21(3):265-70</RefSource><PMID Version="1">6478630</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br Med J (Clin Res Ed). 1987 Apr 11;294(6577):963-5</RefSource><PMID Version="1">3107674</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Endocrinol (Oxf). 1991 Jul;35(1):41-6</RefSource><PMID Version="1">1889138</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002658" MajorTopicYN="N">Developmental Disabilities</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004782" MajorTopicYN="N">Environmental Health</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004785" MajorTopicYN="N">Environmental Pollutants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016021" MajorTopicYN="N">Epidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007037" MajorTopicYN="N">Hypothyroidism</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012924" MajorTopicYN="Y">Social Conditions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>83</NumberOfReferences><OtherID Source="NLM">PMC1240624</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>12</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>24</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>12</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11744507</ArticleId><ArticleId IdType="pii">sc271_5_1835</ArticleId><ArticleId IdType="pmc">PMC1240624</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001547 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001547 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:11744507
|texte= Societal costs of exposure to toxic substances: economic and health costs of four case studies that are candidates for environmental causation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:11744507" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |